Kornimate/medical-research-clean huggingface dataset:
subcutaneous immunotherapy with dermatophagoides pteronyssinus in local allergic rhinitis

Conditions: Local Allergic Rhinitis

Summary: to evaluate the efficacy of an extract of dermatophagoides pteronyssinus versus placebo in the treatment of local allergic rhinitis. the primary efficacy endpoint is the reduction in symptom scores and medication use in the active group compared to placebo. the influence of treatment in "in vitro" and "in vivo" objective parameters was also assessed.


Eligibility criteria:
inclusion criteria: * prior to study specific examinations the patient has to give his/her written informed consent. * local allergic rhinitis induced by dermatophagoides pteronyssinus (dp). * age: 18-55. * negative skin prick-test to dp * positive nasal allergen provocation test to dp (napt-dp) and/or nasal specific ige (sige) to dp\>0.35 ku/l * if applicable negative urine pregnancy test and willingness to use effective form of contraception for the duration of involvement in the study. exclusion criteria: * severe immunopathological or immunodeficiencies diseases. * treatment with beta-blockers, even when administered topically * severe psychological disorders * severe atopic dermatitis * fev1 \<70% predicted after appropriate pharmacological treatment * history of hypersensitivity or intolerance to excipients and / or trial medication or other medication to be used for protocol * inability to adequately perform diagnostic tests or treatment * awareness of other inhaled allergens (perennial or seasonal) clinically relevant to the subject and that may interfere with the response evaluation * treatment with immunotherapy in the 5 years prior to his inclusion in the study

Keywords: local allergic rhinitis subcutaneous immunotherapy house dust mite allergy dermatophagoides pteronyssinus allergy
health care associated infection surveillance in nicu

Conditions: Health Care Associated Infection

Summary: healthcare - associated infection surveillance in neonatal intensive care unit of assiut university children's hospital.the objective of study is to determine the incidence, infection sites, causative organisms and risk factors related to healthcare-associated infections in nicu in assiut university children hospital.

nosocomial infections (nis) are a major public health problem worldwide . nosocomial infections are those acquired in or associated with hospitals. they are also known as hospital-acquired or healthcare-associated infections. the usual deﬁnition of a hospital-acquired infection is one that was not present or incubating when the patient was admitted to a hospital or healthcare facility; where there is doubt, a cut-off period of 48 hours after admission is used.the terms hospital-acquired and healthcare-associated are often used interchangeably, but 'healthcare-associated' also has the wider meaning of any infection acquired as a result of healthcare in any setting. nosocomial infections are common, and may be serious or fatal. some are unavoidable but doctors' duty of care to their patients extends to fundamental matters such as basic hygiene, which may prevent patients becoming infected, and avoidance of unnecessary antibiotics, to discourage development of resistance health care-associated infections (hc-ais) are a major cause of morbidity and mortality in neonatal intensive care units (nicus) and lead to increases in hospital length of stay and treatment cost. higher nosocomial infection incidence in nicus was related to longer duration of hospital stay, and invasive interventions and medical treatments. hc-ais, especially device-associated health care-associated infections (da-hais), were also common in newborns because of their insufﬁcient immune system and mechanical barriers, as well as lack of protective ﬂora

Eligibility criteria:
inclusion criteria: 1. age at admission ( 0-28 day ) 2. neonates who admitted for more than 48 hours exclusion criteria: 1. age:more than 28days 2. neonates who admitted for less than 48 hours. 3. neonates who admitted for infection reasons as (pneumonia, mas, age and skin infection). 4. neonates with potentially infection (prom, chorioamnionitis, tof) 5. neonates with congenital infections
investigation of the characteristics of chronic pain developing after covid-19

Conditions: Covid19; Coronavirus; Chronic Pain

Summary: data on pain after covid-19 were generally collected from hospitalized patients and only include information on acute pain conditions. however, the characteristics of the chronic pain experienced after covid-19 are unknown. for this reason, the treatment and recommendations for patients who present with chronic pain after covid-19 are not clear. our goal is to determine the characteristics and risk factors of chronic pain developing in covid-19 patients and to create specific treatment recommendations for these patient groups with further studies.

data on pain developing after covid-19 were generally collected from hospitalized patients and only include information on acute pain conditions seen after the ilness. it is noteworthy that headache and musculoskeletal pain were seen common in first few weeks. however, the characteristics (mechanical, inflammatory, central sensitization, anxiety-related, etc.) of the chronic pain experienced are unknown. for this reason, the treatment and recommendations for patients who present with chronic pain after covid-19 are not clear. our goal is to determine the characteristics and risk factors of chronic pain developing in covid-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Eligibility criteria:
inclusion criteria: 1. being over the age of 18 2. sars-cov-2 infection demonstrated with the pcr test (testing date irrelevant) 3. pain developed or increased after having covid-19 exclusion criteria: 1. mental retardation or mental status not eligible to answer the questionnaires

Keywords: chronic pain covid19 characteristics
a phase i pharmacologic study of cyc116, an oral aurora kinase inhibitor, in patients with advanced solid tumors

Conditions: Solid Tumors

Summary: this is a phase i study of an investigational cancer drug, cyc116, in patients with advanced solid tumors.

phase i study of an investigational cancer drug, cyc116, an aurora kinase inhibitor, in patients with advanced solid tumors.

Eligibility criteria:
inclusion criteria: * incurable advanced solid tumors that did not respond to conventional therapy or for which no effective therapy exists * age \>=18 years * eastern cooperative oncology group (ecog) performance status 0-2 * life expectancy ≥ 3 months * evaluable disease * adequate bone marrow function * adequate renal function * adequate liver function * at least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities * able to swallow capsules * at least 3 weeks from major surgery * agree to practice effective contraception exclusion criteria: * previously untreated cns metastasis or progressive cns metastasis documented by mri scan performed at 4 weeks or longer after the last treatment for cns metastasis * currently receiving radiotherapy, biological therapy, or any other investigational agents * uncontrolled intercurrent illness * pregnant or lactating women * known to be hiv-positive * known active hepatitis b and/or hepatitis c infection
contrast enhanced swi for carotid plaque imaging

Conditions: Carotid Plaque Imaging

Summary: this study aims to compare image-based characteristics of carotid walls between symptomatic side and the opposite side. the design of this study is phase iv, prospective observational study.

atherosclerosis of craniocervical arteries are one of most important causes of stroke. carotid artery is the most frequent site of atherosclerosis. recent research in carotid artery covers not only morphology of lumen but also direct visualization of carotid plaque or vessel wall. vulnerable carotid plaques share pathologic features of intra-plaque inflammation and hemorrhage. there have been reports about post-contrast swi in the field of vascular imaging. we hypothesized swi is so sensitive to gadolinium based contrast agent and hemorrhage that contrast-enhanced swi can visualize vulnerable carotid plaque. the purpose of this study is to investigate gadolinium-enhanced swi in detection of vulnerable carotid plaque and compare it with mp-rage and dante t1-space. this can be used to guide proper treatment for stroke.

Eligibility criteria:
inclusion criteria: * patients with acute or recent (within 3months) stroke or tia * 50-99% stenosis of internal carotid artery by nascet criteria * written informed consent, prior to registration exclusion criteria: * hemorrhagic stroke * previous history of carotid endarterectomy (cea), angioplasty, or stenting * contraindication for mr imaging * hypersensitivity to gadolinium based contrast media * pregnant or lactating women * patients under age of 19-year-old * renal condition : egfr \< 60 * patients unable and/or unwilling to comply with treatment or study instructions.

Keywords: swi mp-rage dante t1-space
multi-center, pediatric, open-label, preference study of desloratadine 2.5 mg reditab (sch34117) and zyrtec 5.0 mg chewable tablet medications (study p04574)(completed)

Conditions: Allergies

Summary: this was a randomized, open-label, 2-way cross-over study, comparing desloratadine reditab 2.5 mg to a marketed chewable antihistamine oral medication (zyrtec® 5 mg chewable tablet). subject preference for one product or the other was determined. acceptability of product attributes (taste and feeling in the mouth) was rated using a "smile" face scale.


Eligibility criteria:
inclusion criteria: * subject, and the parent/guardian of the subject, was to have demonstrated their willingness to participate in the study and comply with its procedures by signing a written informed consent. * subject was to be 6-11 years of age, of either sex and of any race. * if female, subject was to be premenarcheal. * subject was to be willing to avoid eating, drinking, gum chewing, and teeth brushing for one hour prior to enrollment. * subject was to be free of any clinically significant disease that would interfere with study evaluations, including allergic rhinitis and respiratory infections. * subject was to have understood and been able to adhere to the dosing and visit schedules. exclusion criteria: * if female, subject who was pregnant, intended to become pregnant during the study or nursing. * subject had used any investigational product within 30 days prior to enrollment. * subject had any of the following clinical conditions: history of any significant medical conditions (based on reporting by parent or guardian): e.g., diabetes, heart disease, liver disease, kidney disease, breathing problems, cough with excessive phlegm, or persistent or chronic cough. * subject had a current medical condition that, in the opinion of the investigator or designee, may interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, allergic rhinitis, etc.). * subject was participating in any other clinical study(ies). * subject was part of the staff or a family member of the staff personnel directly involved with this study. * subject was allergic to or has sensitivity to the study drug or its excipients. * subject had a history of allergic reaction to prescription and/or otc medications and/or food products. * subject had used any antihistamines within 24 hours prior to tasting as outlined in section 9.4.7. * subject used sedatives, tranquilizers, or monoamine oxidase inhibitor drugs.
safety and performance of the glyconics-sx system (anode02)

Conditions: Diabetes Mellitus, Type 2

Summary: the main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the glyconics-sx system in distinguishing between individuals with or without t2dm based on known and/or assumed clinical status and as controlled by values of an internal biomarker indicative of glycaemia, hba1c, as measured with a validated comparator device.


Eligibility criteria:
inclusion criteria: * apparently healthy adults (≥18 years of age) with known or unknown t2dm status willing to participate in and provide a written consent for the study * willingness to undertake assisted assessment of glycaemia by both the nir spectra measurement, and hba1c by finger prick test * individuals with two visually assessed apparently healthy, undamaged, and intact fingernails, one in both right- and left-hand middle fingers exclusion criteria: individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as * anaemia (iron deficiency sickle cell anaemia or similar) * haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular assays, * severe renal impairment (ckd stage iii-iv) or decompensated hepatic disease * severe vitamin d deficiency * known severe immunodeficiency such as hiv, malignancy or other chronic condition significantly impacting assessment of glycaemia * eating disorders (as per clinical assessment) * recent (within 28 days) blood donation o any structural, deviating and visually detectable deviations in the appearance of the nails potentially impacting the spectra measurement, including * nail dystrophy or deformity * severe nail infections (onychomycosis causing visual changes in the appearance of the nail) * rare hereditable conditions impacting the structure of keratin * mechanical damage or marks on the surface of the nail after removal of nail polish * use of acrylic or gel nail decoration and polish, which cannot be removed o any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of hba1c value.
preliminary research evaluation for ambulatory leadless electrocardiogram recorder trial

Conditions: Atrial Fibrillation; Tachycardia, Supraventricular; Bradyarrhythmia; Ventricular Arrythmia

Summary: the clinical study is intended to implement and test the collection and analysis of paired ecg data from the heartwatch and two comparator devices, an event recorder and holter. the heartwatch is indicated for extended diagnostic evaluation of patients with transient symptoms of possible cardiac origin such as syncope and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. while the use of the device itself can be managed by both healthcare professionals and patients, interpretation of the collected data for diagnosis is restricted to healthcare professionals, as the data must be loaded and analyzed separately after recording. patients indicated for extended ambulatory ecg testing will be approached for participation. subjects will wear the heartwatch and an event recorder for up to 72 hours or the heartwatch and holter monitor for up to 48 hours. subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). event recorder subjects will collect user-triggered and auto-triggered data, while holter subjects will record diary information on their activities and any relevant symptoms. adverse events and user preference for one device versus the other being used in that arm will also be collected from all subjects. paired ecg data from the heartwatch and comparator devices is expected to be similar in terms of the events documented and the proportion of data that is clinically interpretable.


Eligibility criteria:
inclusion criteria: * at least 22 years of age at time of consent * clinically-indicated for an ambulatory event recorder or holter monitor * able to follow the protocol * provision of written-informed consent exclusion criteria: * known allergy to any component of the event recorder * known allergy to any component of the holter monitor * known allergy to any component of the heartwatch * dextrocardia
efficiency of antagonist drugs of the cellular transcriptomic signature of influenza a virus infection.

Conditions: Flu

Summary: the aim of this study is to evaluate the possibility to repropose marketed drugs as antiviral ones, based on their ability to reverse the transcriptomic signature of the infected cells. this strategy has to be considered is the context of emerging viral diseases and of increase of resistance to antivirals. concerning infection by influenza viruses, the main drugs were identified and evaluated on in vitro and in vivo models: diltiazem. therefore, it will be assess the efficacy of these the drug, compared to placebo, to treat severe flu.


Eligibility criteria:
inclusion criteria: * patients hospitalized in intensive care units, * patients with mechanical ventilation invasive or non-invasive or optiflow® ventilation system. * for a suspicion of severe flu, * with a symptoms for less than 96 hours, * and a respiratory failure defined by the necessity to resort to mechanical ventilation, invasive or optiflow® ventilation system the inclusion is conditioned to the detection of influenza a viruses by pcr on nasopharyngeal swab. exclusion criteria: * no consent. * hypersensibility to oseltamivir * negative pcr on nasopharyngeal swab * symptoms for more than 96 hours. * moribund patients at inclusion. * pregnant/nursing woman. * patients already taking diltiazem in the 48 hours before. * patients having taken more than 3 intakes of oseltamivir before randomization. * hemodynamic instability needing a dose of noradrenaline exceeding 2mg/h contraindication to diltiazem: * sinusal dysfunction without device. * auriculo-ventricular heart block without device. * cardiogenic pulmonary oedema. * left cardiac failure * bradycardia\<40/min * concomitant use of beta-blockers, antiarrythmic drugs, especially amiodarone. * concomitant use of ivabradine, pimozide, nifedipine, ergot alkaloids.

Keywords: infectiology biology of infectious agents flu intensive care
transversus abdominis plane block (tap) for laparoscopic cholecystectomy surgery

Conditions: Cholecystectomy, Laparoscopic; Pain, Postoperative

Summary: postoperative pain is a significant cause of increased morbidity in the perioperative period, leading to patient discomfort and greater hospital length of stay. laparoscopic cholecystectomy associated with significant postoperative pain, a substantial component of which is derived from abdominal wall incisions. ultrasound-guided tap block increasingly has been used for providing pain relief following abdominal surgery. we designed this study with the hypothesis that, administering tap block with levobupivacaine in laparoscopic cholecystectomy provides superior analgesic effects than port-side infiltration.

in this randomized and double-blind study, 75 patients, american society of anesthesiology (asa) i-ii risk group, between the ages of 20-60, who will undergo elective laporoscopic cholecystectomy operation under general anesthesia will be accepted. the patients will be divided into three groups and they will be given postoperative pain treatment with patient-controlled analgesia device. in hours of postoperative 1, 2, 4, 8, 12, 16 and 24, visual analog scale (vas) i (superficial pain), vas ii (deep pain), postoperative total analgesic proportion, nausea and vomiting, evaluation postoperative sedation score will be recorded (as conscious:0, asleep:1, deep sleep:2 ) in hours of postoperative 1, 2, 4, 8, 12, 16 and 24.

Eligibility criteria:
inclusion criteria: * asa i-ii risk group, * between the ages of 20-60, * undergo elective laporoscopic cholecystectomy operation under general anesthesia exclusion criteria: * allergy to anesthetic medication, * coronary artery patients, * obese patients, * emergencies, * pregnants, * abdomen operation history * heart block

Keywords: transversus abdominis plane block levobupivacaine
reducing alcohol use post-bariatric surgery

Conditions: Bariatric Surgery Candidate; Alcohol Drinking

Summary: despite bariatric surgery being the most effective weight loss intervention for patients who are severely obese, as many as 1 in 5 patients will develop an alcohol use disorder after their surgery. changes in metabolism, hormone levels, and behavior as a result of bariatric surgery alter the rewarding effects of alcohol while concurrently changing its absorption rate, putting patients at significantly elevated risk of hazardous drinking. simply providing education to this vulnerable patient population about post-surgical risks has not been sufficient to reduce alcohol use, yet comprehensive in-person interventions are met with significant challenges, including hours-long distances between patients and their bariatric surgery programs. thus, the long-term goal is to increase access to an empirically-supported intervention for reducing alcohol use among patients who undergo bariatric surgery by leveraging technology. this intervention, rooted in motivational interviewing and the transtheoretical model, is a two-session computerized brief intervention cbi, supplemented by six months of tailored text messaging based on participants cbi results and subsequent fluctuations in their readiness to change. the purpose of the proposed study is to optimize this technology-based intervention for patients who undergo bariatric surgery and to examine feasibility and acceptability of the intervention. in the first phase, patient interviews will be utilized to identify preferences for intervention content and treatment delivery. ten patients will then participate in an open trial of the intervention, which will be subsequently revised based on feedback from these patients. in phase 2, patients will be recruited between 3 and 6 months following bariatric surgery and randomized to the intervention or treatment as usual control group. all patients will complete baseline questionnaires and at 1, 3, 6, and 9 month post-assessments. the investigators expect that this intervention will be both feasible and acceptable to patients. results will be used as preliminary data to inform a large, fully-powered clinical trial to test the larger efficacy of this intervention.


Eligibility criteria:
inclusion criteria: * underwent a bariatric surgery procedure between 3 and 6 months prior to the recruitment date * has not consumed alcohol since undergoing bariatric surgery exclusion criteria: * history of an alcohol use disorder * never consumed alcohol prior to surgery * does not have a cellular phone that can receive and send text messages * no access to internet to complete the computerized brief intervention (cbi)
shiga progression of diabetes, nephropathy and retinopathy

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to investigate whether the oral anti-diabetic drug, thiazolidine (tzd) is effective in suppression of onset or progressin of diabetic nephropathy in japanese type 2 diabetic patients.

2. outcome measures: 1. primary endpoint onset or progression of diabetic nephropathy 2. secondary endpoints (1)progression of diabetes mellitus (2)change in hba1c (3)change in albumin-creatinine ratio (4)change in gfr (5)change in cystatin c

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * less than 8.0% in hba1c * less than 300 mg/g cr of urinary albumine level * concomitant therapy with su and/or biguanide * untreated hypertension and hypertension treated with arb or acei exclusion criteria: * history of heart failure and concomitant heart failure * history of administration of tzd agent * severe hepatic dysfunction with more than 3 times higher than upper limit of normal range of got, gpt or rgpt * severe renal dysfunction with more than 2.5 of cr * history of ae with tzd agent * insulin treatment * concomitant urinary track infection

Keywords: type 2 diabetes mellitus diabetic nephropathy diabetic retinopathy pioglitazone